Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Clin Lab Med. 2021 Sep;41(3):341-357. doi: 10.1016/j.cll.2021.04.005. Epub 2021 Jul 2.
Immunotherapy marked a milestone in cancer treatment and has shown unprecedented efficacy in a variety of hematological malignancies. Downregulation or loss of target antigens is commonly seen after immunotherapy, which often causes diagnostic dilemma and represents a key mechanism that tumor escapes from immunotherapy. The awareness of phenotypic changes after targeted immunotherapy is important to avoid misdiagnosis. Further understanding of the mechanisms of antigen loss is paramount for the development of therapeutic approaches that can prevent or overcome antigen escape in future immunotherapy.
免疫疗法标志着癌症治疗的一个里程碑，在多种血液系统恶性肿瘤中显示出了前所未有的疗效。免疫治疗后，靶抗原的下调或缺失很常见，这往往导致诊断上的困境，也是肿瘤逃避免疫治疗的一个关键机制。了解靶向免疫治疗后的表型变化对于避免误诊很重要。进一步了解抗原丢失的机制对于开发未来免疫治疗中预防或克服抗原逃逸的治疗方法至关重要。
